KRAS and lung adenocarcinoma: These mouse crossings were designed to simultaneously induce the LSL–Kras-G12D mutation and delete the integrin β1 subunit in type 2 alveolar (AT2) cells, the cell of origin for lung adenocarcinoma (17), in an inducible fashion.